Medigen Vaccine Biologics and BlueWillow Biologics have partnered for development of S-2P-NE-01, an intranasal vaccine against the SARS-CoV-2 virus, the companies said. According to the announcement, the vaccine will include BlueWillow’s NanoVax nasal vaccine adjuvant and Medigen’s S-2P spike protein; preclinical studies in mice have shown that the combination produced a significant neutralizing antibody response and a high mucosal immune response.
BlueWillow Biologics CEO Chad Costley commented, “Our partnership with MVC is a tremendous milestone in our plan to develop a nasal vaccine for SARS-CoV-2 and we are buoyed by the preclinical results showing that intranasal vaccination with S-2P-NE-01 holds great promise for both mucosal and serologic immunity to SARS-CoV-2. Our plan is to rapidly advance S-2P-NE-01 into human clinical trials as we move forward to battle this global pandemic.”
Medigen CEO Charles Chen said, “As the COVID-19 pandemic continues to spread around the world, there is an urgent need to develop a vaccine to fight this global crisis and we are proud to partner with BlueWillow to create an intranasal vaccination that has the potential to save human lives. While there has been a lot of movement in the development of vaccines, research continues to show the vast benefits of an intranasal vaccination and we look forward to the ongoing clinical development of our product candidate.”
BlueWillow’s pipeline also includes intranasal vaccines based on its NanoVax technology for the prevention of anthrax, influenza, respiratory syncytial virus (RSV), tuberculosis, and herpes simplex virus (HSV).
Read the BlueWillow Biologics and Medigen Vaccine Biologics press release.
